IFP Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

IFP Advisors’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-53	Closed	–	–	4234
2018 Q1	$0	Hold	53	–	–	﹤0.01%	3915
2017 Q4	$0	Hold	53	–	–	﹤0.01%	4337
2017 Q3	$0	Hold	53	–	–	﹤0.01%	4343
2017 Q2	$0	Hold	53	–	–	﹤0.01%	4341
2017 Q1	$0	Hold	53	–	–	﹤0.01%	4267
2016 Q4	$0	Buy	53 +25	+89%	+$162	﹤0.01%	4255
2016 Q3	$0	Hold	28	–	–	﹤0.01%	4164
2016 Q2	$0	Buy	+28	New	+$190	﹤0.01%	4224
2016 Q1	–	Sell	-169	Closed	-$2K	–	3985
2015 Q4	$2K	Buy	+169	New	+$2.91K	﹤0.01%	3431

IFP Advisors's CASC Position: Q2 2018 in Review

IFP Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2018, closing a stake of 53 shares.

IFP Advisors first reported a position in CASC in Q4 2015 and held it in 9 quarters. The position peaked at $2K in Q4 2015. 0 funds tracked by Wall St. Rank hold CASC as of Q2 2018.

IFP Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
IFP Advisors sold 53 Cascadian Therapeutics, Inc. shares in Q2 2018.
IFP Advisors first reported a position in Cascadian Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
IFP Advisors's Cascadian Therapeutics, Inc. position peaked at $2K in Q4 2015.
0 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2018.

Based on IFP Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.